manilatimes.netJUN 12 min read$HELP

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York

Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) said interim CEO Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on June 4, 2026 at 2:35 p.m. EDT. The webcast will be available live, with a replay on the company’s investor relations site.

Original reporting

manilatimes.net

Published Jun 1, 2026, 12:00 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Jun 1, 2026, 12:46 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

Helus Pharma to Participate in the Jefferies Global Healthcare Conference in New York — source image — Source · manilatimes.net

Decision brief

The 30-second read

$HELPNeutralLow

Why it matters

This announcement primarily sets expectations for management visibility at a healthcare conference; it does not disclose new efficacy/safety, FDA/other regulatory actions, or financing/partnership terms.

Market read

Potential for sentiment drift into the webcast, but no actionable new fundamentals are provided in the release.

What to watch

Watch for any subsequent press release or investor deck tied to the fireside chat; absent that, the scheduling news is unlikely to re-rate the stock.

Relevance 4/10Novelty 3/10Timing: Ahead of the June 4, 2:35 p.m. EDT fireside chat webcast

Background

Helus Pharma (commercial operating name of Cybin Inc.) is a clinical-stage serotonergic agonist developer with programs including HLP003 (Phase 3, adjunctive MDD) and HLP004 (Phase 2, GAD).

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$HELPNeutralHigh confidence

Context

Helus Pharma (HELP) announced interim CEO Eric So will present at the Jefferies Global Healthcare Conference, with a webcast scheduled June 4.

Expected impact

Low near-term impact; any price move would likely depend on what is said during the fireside chat, not disclosed here.

Evidence & confidence

The article is purely an investor-conference scheduling update and does not provide incremental results, guidance, or deal/regulatory outcomes.

Market effects

Sector

Minimal; conference participation is common for biotech and does not change sector fundamentals by itself.

Regional

Minimal; the event is in New York but the company’s operations are multi-region.

Global

Low; no international regulatory or partnership developments are mentioned.

Counterpoint

What could challenge this read

Traders may treat the event as a potential venue for incremental trial updates; however, this specific release does not include any such information.

Key entities

executive
Eric So
Interim CEO of Helus Pharma scheduled to participate in the Jefferies fireside chat.
event
Jefferies Global Healthcare Conference
New York conference (June 2-4, 2026) where the webcast will be available June 4 at 2:35 p.m. EDT.

Read at source ← All news

JUL 21

$HELPMed

Helus Pharma Completes Enrollment in Phase 3 APPROACH Study of HLP003 in Adjunctive Treatment of Major Depressive Disorder Ahead of Schedule

Helus Pharma (Nasdaq: HELP) said it completed enrollment in its Phase 3 APPROACH study of HLP003, an investigational adjunctive treatment for major depressive disorder, ahead of schedule. The company reported 223 enrolled participants and expects topline data in Q4 2026. Phase 2 results cited include ~23-point MADRS reduction and 100% response/71% remission.

prnewswire.com2 min

JUL 21

$HELPMed

Helus Pharma stock jumps on Phase 3 enrollment completion By Investing.com

Helus Pharma (NASDAQ:HELP) shares rose 12.4% after the company said it completed enrollment in its APPROACH Phase 3 trial of HLP003 for major depressive disorder. The study enrolled 223 adults; topline data are expected in Q4 2026. APPROACH is one of two pivotal trials, with EMBRACE ongoing.

investing.com3 min

JUL 17

$LLYMedAI 8/10

Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time

Eli Lilly (NYSE: LLY) agreed to acquire AtaiBeckley Inc. (NASDAQ: ATAI) for $6.75 per share in cash (about $2.8B) plus up to $2.50 per share in milestone-linked contingent value rights, totaling up to about $3.8B. The deal was approved by both boards and is expected to close in Q3. The article cites Helus Pharma (NASDAQ: HELP) Phase 3 readout in Q4 2026.

prnewswire.com7 min

JUN 25

$HELPMedAI 8/10

Helus Pharma™ Announces Closing of US$50 Million Underwritten Offering

Helus Pharma (Nasdaq: HELP; Cboe CA: HELP) said it closed a previously announced underwritten offering of 10,309,280 common shares at US$4.85 each, raising US$50 million in gross proceeds. Cantor and Barclays were joint bookrunners; Bloom Burton and Lucid were lead managers. Net proceeds will fund Phase 3 HLP003 (MDD) with data expected in Q4 2026, plus HLP004 and HLP005, and for working capital.

montrealgazette.com2 min

AUG 8

$SUNEMedAI 8/10

Pentagon to invest $400m in Australian rare earth mine

Sunrise Energy Metals said the US Pentagon will provide a conditional $400 million loan commitment to develop Syerston, a proposed scandium mine in Fifield, NSW. The project targets Western supply of scandium used in defence and other sectors amid China’s export restrictions. Sunrise also said it has a deal with Lockheed Martin for 25% of output for five years.

bssnews.net4 min